Analysis of emergency Drug Approval System in China and the United States under Public Health emergencies and its enlightenment to China
Abstract
Objective: Public health emergencies, such as COVID-19, put forward a severe test to the response system of countries all over the world, including China. Especially under such conditions, the establishment and operation of the emergency drug approval system is particularly important. The purpose of this paper is to compare and analyze the emergency drug approval system between China and the United States, and learn from the experience of developed countries to improve China's drug review capability in response to public health emergencies.
This paper mainly analyzes the emergency drug approval system of China and the United States under public health emergencies through literature research and comparative analysis theory. Although there are four channels to accelerate the approval of drugs for listing in China, none of them can solve the problem of emergency drug use in the face of public health emergencies, and cannot become the policy basis for the use of unlisted drugs or drugs beyond the instructions.
Conclusion: On the basis of maintaining China's own institutional advantages and drawing on foreign experience, this paper puts forward relevant policy recommendations to improve China's emergency drug approval system in the event of public health emergencies.
Downloads
References
http://www.gov.cn/zhengce/2020-12/26/content_5574586.htm
2. Yanan Wang, Rong Jiang, Rong Shao. Research on Emergency Approval System of Pharmaceutical Products in China under Public Health Emergencies. Chinese Journal of Pharmaceuticals. 2022; 53(1):140-147.
3. Juan Chen, Yan Lu, Dongzi Xu, et al. System Problems and Recommendations for the Emergency Use of Drugs in China. China Pharmaceuticals. 2021; 30(14):6-10.
4. Provisions of the People's Republic of China for the Administration of Drug Registration [Internet]. China: State Administration for Market Regulation; 2020 Mar 30 [cited 2022 Nov 10]. Available from:
https://gkml.samr.gov.cn/nsjg/fgs/202003/t20200330_313670.html
5. Vaccine Administration Law of the People's Republic of China [Internet]. China: Center for Drug Evaluation, NMPA; 2019 Jul 2 [cited 2022 Nov 10]. Available from: https://www.cde.org.cn/main/policy/view/4568289019d49f2f7d2a7daf35c5371e
6. Xue Wang, Shuning Zuo, Qi Zhang, et al. Analysis on emergency authorization policies of medical products. Chinese Journal of New Drugs. 2021; 30(7):596-600
7. Technical Guidelines for Conditional Approval of Drugs for Marketing (Trial) [Internet]. China: Center for Drug Evaluation, NMPA; 2020 Nov 19 [cited 2022 Nov 10]. Available from:
https://www.cde.org.cn/main/news/viewInfoCommon/d1716db06f90c3adf134de337373b22c
8. Emergency Use Authorization of Medical Products and Related Authorities [Internet]. US: FDA; 2017 Jan 17 [cited 2022 Nov 10]. Available from:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities
9. What are Medical Countermeasures? [Internet]. US: FDA; 2022 Mar 16 [cited 2022 Nov 10]. Available from:
https://www.fda.gov/emergency-preparedness-and-response/about-mcmi/what-are-medical-countermeasures
10. GAO. DRUG DEVELOPMENT FDA’s Priority Review Voucher Programs [Internet]. US: United States Government Accountability Office; 2020 Jan 20 [cited 2022 Nov 10]. Available from:
https://www.gao.gov/assets/gao-20-251.pdf
11. Material Threat Medical Countermeasure Priority Review Vouchers [Internet].US: FDA; 2018 Jan 17 [cited 2022 Nov 10]. Available from:
https://www.fda.gov/media/110193/download
12. Xuanwei Zhong, Ruosi Han, Bo Li. The Analysis and Consideration for Emergency Policies of Medical Products Used for Dealing with Public Health Emergency in China and US. Chinese Pharmaceutical Journal. 2020;55(23):1979-1984.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
